127.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories Stock (ABT) Latest News
Abbott’s world-first portable whole blood rapid test for concussions launches in the UK (2) - PharmiWeb.com
U.S. Clinical Nutrition Market Is Booming Worldwide 2025-2032 | - openPR
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
Abbott launches portable concussion blood test in UK - Medical Device Network
Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating! - Smartkarma
Brazil Enteral Nutrition Market Is Booming Worldwide 2025-2032 - openPR
Medical Nutrition Market Key Players Analysis- Abbott - openPR
RFK Jr.’s Next Targets Are Companies Making Baby Formula - Yahoo Finance
US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com
Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Personalized Vitamins Market Top Players- BASF SE, Abbott Laboratories. Amway Corporation, Bayer AG, Caligenix. - openPR
Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio - Morningstar
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - MSN
Blood Typing Analysis Report 2024: Market Set to Surge to $6.50 Billion by 2034, PCR and Microarray Techniques Pave the Way - GlobeNewswire Inc.
Abbott Stock Could Be On The Verge Of A Breakout — Here’s What Smart Money Sees (NYSE:ABT) - Seeking Alpha
Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula case - just-food.com
Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) earnings growth rate lags the 15% CAGR delivered to shareholders - Simply Wall St
Abbott Laboratories Basking In A Sharp Turn In Sentiment (NYSE:ABT) - Seeking Alpha
Why Abbott Laboratories (ABT) Went Down On Thursday? - MSN
Why Abbott Laboratories (ABT) Went Down On Friday? - Insider Monkey
Abbott Labs, Reckitt Benckiser Shares Fall After New Ruling on Infant Formula Case - The Wall Street Journal
Baby Formula Makers Abbott and Reckitt See Stocks Slide as Judge Allows Retrial - Investopedia
In a setback for Abbott Laboratories, judge allows new trial in case over formula for premature infants - Chicago Tribune
Judge Vacates Baby Formula Trial Win For Abbott, Mead - Law360
‘A Manifest Injustice': Judge Who Sanctioned Abbott’s Counsel Grants New Infant Formula Trial - Law.com
Sector Update: Health Care -March 14, 2025 at 03:29 pm EDT - Marketscreener.com
BofA keeps $150 target on Abbott Labs stock amid retrial news - Investing.com
Abbott, Reckitt Fall as Judge Grants New Trial on Infant Formula - Bloomberg
Abbott, Reckitt face new trial over premature infant formula - Reuters
That baby formula trial Abbott and Reckitt won isn't over just yet - Crain's Chicago Business
Judge orders retrial in Abbott, Reckitt infant formula case - Seeking Alpha
Citi maintains Abbott stock Buy rating, $160 target amid legal updates By Investing.com - Investing.com South Africa
Is Abbott Laboratories (ABT) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Citi maintains Abbott stock Buy rating, $160 target amid legal updates - Investing.com
Abbott, Reckitt face new trial over premature infant formula -March 14, 2025 at 11:09 am EDT - Marketscreener.com
Positive Long-Term Outlook for Abbott Laboratories Despite Short-Term NEC Litigation Risks - TipRanks
Abbott sends film crew to highlight partnership with Auburn Community Hospital - The Citizen
Abbott stock falls following retrial order in infant formula case - Investing.com
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Abbott (ABT) Stock Moves -0.3%: What You Should Know - Nasdaq
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - MSN
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Glucose Biosensor Market Booming with Technological Advancements | Industry Insights Abbott Laboratories, - EIN News
Here's Why We Think Abbott Laboratories (NYSE:ABT) Might Deserve Your Attention Today - Yahoo Finance
OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News
EPD Expansion Supports Abbot Stock, Macro Issues Prevail - TradingView
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Abbott Laboratories (NYSE:ABT) Given New $150.00 Price Target at Bank of America - Defense World
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Benzinga
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):